Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Arno Gielkens is active.

Publication


Featured researches published by Arno Gielkens.


Journal of Virology | 2000

Rescue of Very Virulent and Mosaic Infectious Bursal Disease Virus from Cloned cDNA: VP2 Is Not the Sole Determinant of the Very Virulent Phenotype

Hein J. Boot; Agnes ter Huurne; Arjan J. W. Hoekman; Ben Peeters; Arno Gielkens

ABSTRACT Many recent outbreaks of infectious bursal disease in commercial chicken flocks worldwide are due to the spread of very virulent strains of infectious bursal disease virus (vvIBDV). The molecular determinants for the enhanced virulence of vvIBDV compared to classical IBDV are unknown. The lack of a reverse genetics system to rescue vvIBDV from its cloned cDNA hampers the identification and study of these determinants. In this report we describe, for the first time, the rescue of vvIBDV from its cloned cDNA. Two plasmids containing a T7 promoter and either the full-length A- or B-segment cDNA of vvIBDV (D6948) were cotransfected into QM5 cells expressing T7 polymerase. The presence of vvIBDV could be detected after passage of the transfection supernatant in either primary bursa cells (in vitro) or embryonated eggs (in vivo), but not QM5 cells. Rescued vvIBDV (rD6948) appeared to have the same virulence as the parental isolate, D6948. Segment-reassorted IBDV, in which one of the two genomic segments originated from cDNA of classical attenuated IBDV CEF94 and the other from D6948, could also be rescued by using this system. Segment-reassorted virus containing the A segment of the classical attenuated isolate (CEF94) and the B segment of the very virulent isolate (D6948) is not released until 15 h after an in vitro infection. This indicates a slightly retarded replication, as the first release of CEF94 is already found at 10 h after infection. Next to segment reassortants, we generated and analyzed mosaic IBDVs (mIBDVs). In these mIBDVs we replaced the region of CEF94 encoding one of the viral proteins (pVP2, VP3, or VP4) by the corresponding region of D6948. Analysis of these mIBDV isolates showed that tropism for non-B-lymphoid cells was exclusively determined by the viral capsid protein VP2. However, the very virulent phenotype was not solely determined by this protein, since mosaic virus containing VP2 of vvIBDV induced neither morbidity nor mortality in young chickens.


Vaccine | 2001

Generation of a recombinant chimeric Newcastle disease virus vaccine that allows serological differentiation between vaccinated and infected animals.

Ben Peeters; Olav S. de Leeuw; Iwan Verstegen; G. Koch; Arno Gielkens

Using a recently developed reverse genetics system, we have generated a recombinant Newcastle disease virus (NDV) vaccine in which the gene encoding the hemagglutinin-neuraminidase (HN) has been replaced by a hybrid HN gene consisting of the cytoplasmic domain, transmembrane region, and stalk region of HN of NDV, and the immunogenic globular domain of HN of avian paramyxovirus type 4 (APMV4). The objective was to generate a chimeric live vaccine that induces a protective immune response against NDV by eliciting neutralizing antibodies against the fusion (F) protein, but which can be differentiated from wild-type NDV on the basis of different antibodies elicited by their HN proteins. Pathogenicity tests in day-old chickens showed that the recombinant was non-virulent (intracerebral pathogenicity index [ICPI]=0.00). A vaccination-challenge experiment in 4-week-old specific pathogen free chickens demonstrated that the recombinant was completely safe and was able to protect chickens from challenge with a lethal dose of virulent NDV. By using a secreted form of HN produced in Pichia pastoris, a test was developed that allowed serological differentiation between animals vaccinated with the recombinant vaccine and animals infected with NDV. These results demonstrate that genetically modified marker vaccines can be generated from small RNA viruses that lack non-essential genes.


Journal of General Virology | 2000

Interactions in vivo between the proteins of infectious bursal disease virus: capsid protein VP3 interacts with the RNA- dependent RNA polymerase, VP1

Mirriam Tacken; Peter J. M. Rottier; Arno Gielkens; Ben Peeters

Little is known about the intermolecular interactions between the viral proteins of infectious bursal disease virus (IBDV). By using the yeast two-hybrid system, which allows the detection of protein-protein interactions in vivo, all possible interactions were tested by fusing the viral proteins to the LexA DNA-binding domain and the B42 transactivation domain. A heterologous interaction between VP1 and VP3, and homologous interactions of pVP2, VP3, VP5 and possibly VP1, were found by co-expression of the fusion proteins in Saccharomyces cerevisiae. The presence of the VP1-VP3 complex in IBDV-infected cells was confirmed by co-immunoprecipitation studies. Kinetic analyses showed that the complex of VP1 and VP3 is formed in the cytoplasm and eventually is released into the cell-culture medium, indicating that VP1-VP3 complexes are present in mature virions. In IBDV-infected cells, VP1 was present in two forms of 90 and 95 kDa. Whereas VP3 initially interacted with both the 90 and 95 kDa proteins, later it interacted exclusively with the 95 kDa protein both in infected cells and in the culture supernatant. These results suggest that the VP1-VP3 complex is involved in replication and packaging of the IBDV genome.


Journal of General Virology | 1997

Biologically safe, non-transmissible pseudorabies virus vector vaccine protects pigs against both Aujeszky's disease and classical swine fever

Ben Peeters; Krystyna Bieńkowska-Szewczyk; Marcel Hulst; Arno Gielkens; Tjeerd G. Kimman

Envelope glycoprotein D (gD) of pseudorabies virus (PRV) is essential for penetration but is not required for cell-to-cell spread. When animals are inoculated with a phenotypically complemented PRV gD mutant, the virus is able to spread locally by means of direct cell-to-cell transmission, but progeny virions released by infected cells are non-infectious because they lack gD. Therefore, the virus cannot be transmitted from inoculated animals to other animals. This property makes a PRV gD mutant an attractive candidate as a safe vaccine vector. To examine whether a self-restricted, non-transmissible PRV mutant can be used as a biologically safe vaccine vector, a gD/gE-negative PRV recombinant virus which expresses envelope glycoprotein E2 of classical swine fever virus was constructed. Vaccination of pigs showed that the recombinant virus was able to protect pigs against both Aujeszkys disease and classical swine fever.


Journal of Virology | 2002

Exchange of the C-Terminal Part of VP3 from Very Virulent Infectious Bursal Disease Virus Results in an Attenuated Virus with a Unique Antigenic Structure

Hein J. Boot; Agnes ter Huurne; Arjan J. W. Hoekman; Jan M.A. Pol; Arno Gielkens; Ben Peeters

ABSTRACT Infectious bursal disease virus (IBDV) is the major viral pathogen in the poultry industry. Live attenuated serotype 1 vaccine strains are commonly used to protect susceptible chickens during their first 6 weeks of life. Wild-type serotype 1 IBDV strains are highly pathogenic only in chickens, whereas serotype 2 strains are apathogenic in chickens and other birds. Here we describe the replacement of the genomic double-stranded RNA (dsRNA) encoding the N- or C-terminal part of VP3 of serotype 1 very virulent IBDV (vvIBDV) (isolate D6948) with the corresponding part of serotype 2 (isolate TY89) genomic dsRNA. The modified virus containing the C-terminal part of serotype 2 VP3 significantly reduced the virulence in specific-pathogen-free chickens, without affecting the distinct bursa tropism of serotype 1 IBDV strains. Furthermore, by using serotype-specific antibodies we were able to distinguish bursas infected with wild-type vvIBDV from bursas infected with the modified vvIBDV. We are currently evaluating the potential of this recombinant strain as an attenuated live vaccine that induces a unique serological response (i.e., an IBDV marker vaccine).


Vaccine | 1994

Non-transmissible pseudorabies virus gp50 mutants : a new generation of safe live vaccines

Ben Peeters; A. Bouma; Tiny de Bruin; R.J.M. Moormann; Arno Gielkens; Tjeerd G. Kimman

Envelope glycoprotein gp50 of pseudorabies virus (PRV) is essential for virus entry, but is not required for subsequent steps in the viral replication cycle. Phenotypically-complemented gp50 null mutants can infect cells and can spread, both in vitro and in vivo, by direct cell-to-cell transmission. However, progeny virions released by the infected cells are non-infectious because they lack gp50. Therefore, these viruses cannot be transmitted from infected animals to contact animals. These properties could make PRV gp50 null mutants attractive candidates as safe non-transmissible live vaccines. To establish whether phenotypically-complemented PRV gp50 null mutants and gp50 + gp63 double mutants could be used as live vaccines against Aujeszkys disease, the virulence and immunogenicity of these mutants were tested in pigs. Our results show that a gp50 null mutant has a greatly reduced virulence for pigs, and that pigs immunized with such a mutant were protected from clinical signs of Aujeszkys disease after a challenge inoculation with the virulent wild-type PRV strain NIA-3. PRV gp50 + gp63 deletion mutants proved to be non-virulent for pigs and were somewhat less immunogenic, since immunized animals showed some fever and growth retardation after challenge inoculation. Replication of wild-type challenge virus was significantly reduced, but could not completely be prevented, in pigs immunized with a gp50 null mutant, and was reduced less in pigs immunized with a gp50 + gp63 deletion mutant. Furthermore, infectious virus could not be recovered from oropharyngeal fluid or tissues from pigs inoculated with a gp50 null mutant or a gp50 + gp63 deletion mutant.(ABSTRACT TRUNCATED AT 250 WORDS)


Avian Pathology | 2003

Tissue tropism in the chicken embryo of non-virulent and virulent Newcastle diseases strains that express green fluorescence protein.

S.O. Al-Garib; Arno Gielkens; E. Gruys; Ben Peeters; G. Koch

The tissue tropism of non-virulent and virulent Newcastle disease virus (NDV) was investigated using 8-day-old and 14-day-old embryonating chicken eggs (ECE), inoculated with an infectious clone of the non-virulent La Sota strain (NDFL-GFP) or its virulent derivative (NDFLtag-GFP). Both strains expressed the gene encoding jellyfish green fluorescence protein (GFP) as a marker. The GFP was readily expressed in chicken embryo cells infected with the NDV strains indicating virus replication. Whereas both strains replicated in the chorioallantoic membrane (CAM) and infected the skin of 8-day-old ECE, only the virulent strain (NDFLtag-GFP) spread to internal organs (pleura/peritoneum). In 14-day-old ECE, the initial target organs appeared to be the CAM and the lungs for both strains. At 48 h after inoculation, the virulent strain (NDFLtag-GFP) had also spread to the spleen and heart and was detected in a wide-range of embryonic cell types. The kinetics of virus replication and spread in the CAM closely resembled each other in both the 8-day-old and 14-day-old ECE. Infection of 8-day-old and 14-day-old ECE forms a convenient model to investigate tissue tropism of NDV, as well as the kinetics of viral infection. The advantage of using GFP is that samples can be easily screened by direct fluorescence microscopy without any pre-treatment.


Archives of Virology | 2001

Rescue of infectious bursal disease virus from mosaic full-length clones composed of serotype I and II cDNA

Hein J. Boot; A. A. H. M. ter Huurne; S. A. Vastenhouw; A. Kant; Ben Peeters; Arno Gielkens

Summary. Infectious Bursal Disease Virus (IBDV) is the causative agent of one of the most important and wide-spread infectious diseases among commercial chicken flocks. IBDV causes a depletion of B-lymphoid cells in the bursa of Fabricius, inducing immunosuppression, morbidity, or even acute mortality. Because currently used live IBDV vaccines are derivatives from field isolates no serologic discrimination between field isolates and live vaccines can be made. The recently developed reverse genetics techniques for IBDV allows one to generate genetically modified IBDVs which might have altered biological and antigenic properties. Here, we describe the rescue of mosaic serotype I IBDVs, of which the polyprotein encoding region was partly replaced by the corresponding region of a serotype II strain. A mosaic virus, containing the C-terminal part of serotype II VP3 showed only a slightly delayed release of progeny virus compared to unmodified serotype I virus, while maximum viral titers at 25 h post infection were equal. Since serotype specific epitope(s) are present in the C-terminal part of VP3, we were able to discriminate this rescued virus from serotype I and II IBDV strains. These findings make the use of a chimeric VP3 a promising approach to develop an IBDV marker vaccine.


Veterinary Microbiology | 1992

Effects of replacing the promoter of the immediate early gene with the promoter of drosophila heat-shock gene HSP70 on the growth and virulence of pseudorabies virus

Koen Glazenburg; Arno Gielkens; Rob J.M. Moormann

We investigated whether altering control of expression of an essential gene of pseudorabies virus (PRV) influences virus replication and virulence. The PRV immediate early (IE) gene was selected as a target, and its promoter was replaced with the promoter of the heat-shock gene HSP70 of the fruit fly Drosophila. The HSP70 promoter was selected because it is well characterized and can be induced in a broad range of eukaryotic cell lines at temperatures around 42 degrees C. Overlap recombination was used to construct the NIA3-HSP mutant virus. When stocks of the recombinant virus were titrated at 42 degrees C, virus titres were 100 times higher than titres obtained at 37 degrees C. Once replication began, however, the rate of growth of the mutant NIA3-HSP was equal at both temperatures. When wild-type virus was titrated at both temperatures, titres were identical. Mice that were infected with the mutant virus had a longer mean-time-to-death than those infected with the wild-type virus. Thus, the mutant virus was considered to be less virulent. We conclude that replication and virulence of PRV can be modified by altering control of expression of the viral IE gene.


Acta Agriculturae Scandinavica Section A-animal Science | 2004

Delayed type hypersensitivity reaction as indicator of cellular immune competence in broiler chickens exposed to dietary corticosterone

J. Post; Arno Gielkens; A.A.H.M. ter Huurne

Three experiments were performed to evaluate the delayed type hypersensitivity test against keyhole limpet haemocyanin as a parameter to measure stress-induced cellular immune suppression. The test was optimised for broiler chickens and evaluated in a stress model in which plasma corticosterone levels were increased by the administration of 0.5 or 2 mg corticosterone/chicken/day. Keyhole limpet haemocyanin evoked a hypersensitivity type IV response, which was sensitive to increased plasma corticosterone levels. However, the inhibitory effect of 0.5 mg corticosterone/chicken/day was not significantly different from the solvent control (ethanol), because of an inhibitory effect of ethanol itself. The inhibitory effect of 2 mg corticosterone/chicken/day was mainly due to an effect on female chickens, indicating a difference in corticosterone sensitivity between gender. Our data indicate that the delayed type hypersensitivity test against keyhole limpet haemocyanin was sensitive for increased plasma corticosterone concentrations. Therefore this may be an easy and useful test for measuring cell-mediated immunity in corticosterone related immune-suppressed broiler chickens.

Collaboration


Dive into the Arno Gielkens's collaboration.

Top Co-Authors

Avatar

Ben Peeters

Wageningen University and Research Centre

View shared research outputs
Top Co-Authors

Avatar

R.J.M. Moormann

Wageningen University and Research Centre

View shared research outputs
Top Co-Authors

Avatar

G. Koch

Wageningen University and Research Centre

View shared research outputs
Top Co-Authors

Avatar

Tjeerd G. Kimman

Wageningen University and Research Centre

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anton Berns

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Olav S. de Leeuw

Wageningen University and Research Centre

View shared research outputs
Researchain Logo
Decentralizing Knowledge